Colin Love
Director/Board Member at Replimune Ltd.
Net worth: 4 M $ as of 2024-05-30
Profile
Colin A.
Love was the founder of Replimune Group, Inc. (founded in 2015) where he held the title of Chief Operating Officer from 2015 to 2024.
He is currently working as a Non-Executive Director at Freeline Therapeutics Ltd., as a Director at Replimune Ltd., and as a Director at Replimune (Ireland) Ltd.
Dr. Love has previously worked as a Director-Manufacturing Development at Celltech Group Plc, as an Independent Non-Executive Director at Freeline Therapeutics Holdings Plc from 2021 to 2024, as a Vice President-Clinical Operations at Amgen, Inc. from 2011 to 2014, as a Senior Vice President-Product Development at BioVex, Inc. from 2000 to 2011, as a Senior Vice President-Product Development at BioVex Group, Inc. from 2000 to 2013, and as a Senior Vice President-Product Development at BioVex Ltd.
Dr. Love has an undergraduate and doctorate degree from the University of Glasgow.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
REPLIMUNE GROUP, INC.
1.27% | 2024-05-15 | 777,345 ( 1.27% ) | 4 M $ | 2024-05-30 |
Colin Love active positions
| Companies | Position | Start |
|---|---|---|
Replimune Ltd.
 Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The company is based in Abingdon, UK and was founded in 2015. | Director/Board Member | 2017-07-09 |
Replimune (Ireland) Ltd.
 Replimune (Ireland) Ltd. Miscellaneous Commercial ServicesCommercial Services Replimune (Ireland) Ltd., part of Replimune Group, Inc., is a company headquartered in Dublin, Ireland. The firm provides professional, scientific and technical services. | Director/Board Member | 2019-09-30 |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Former positions of Colin Love
| Companies | Position | End |
|---|---|---|
| REPLIMUNE GROUP, INC. | Founder | 2024-05-30 |
| FREELINE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 2024-02-19 |
BioVex Ltd.
 BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | 2015-07-30 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 2013-12-31 |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Corporate Officer/Principal | 2013-01-23 |
Training of Colin Love
| University of Glasgow | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| REPLIMUNE GROUP, INC. | Health Technology |
| Private companies | 8 |
|---|---|
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Replimune Ltd.
Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The company is based in Abingdon, UK and was founded in 2015. | Commercial Services |
Replimune (Ireland) Ltd.
Replimune (Ireland) Ltd. Miscellaneous Commercial ServicesCommercial Services Replimune (Ireland) Ltd., part of Replimune Group, Inc., is a company headquartered in Dublin, Ireland. The firm provides professional, scientific and technical services. | Commercial Services |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Colin Love
